Bylvay backers buoyed as new nod brings relief for chronic illness

14 June 2023

Just months after France’s Ipsen (Euronext: IPN) bought liver disease specialist Albireo, the company’s main product Bylvay (odevixibat) has won a new US nod.

Albireo’s scientists have been exploring the therapeutic potential of bile-acid modulators, gaining approval in 2021 to treat cholestatic pruritus from progressive familial intrahepatic cholestasis (PFIC).

Bylvay can now be marketed for people with Alagille syndrome who suffer the same intense itching, making it a direct competitor to Mirum Pharmaceuticals’ (Nasdaq: MIRM) Livmarli (maralixibat).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK